| Document |
Document Title |
|
WO/2017/127820A1 |
Disclosed herein, in part, are compounds and methods for their use in the treatment of malaria. In at least one specific embodiment, the compounds or salts thereof can include compounds of Formula (I):
|
|
WO/2017/105040A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure can provide an organic electrolumine...
|
|
WO/2017/060167A1 |
The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular o...
|
|
WO/2017/021805A1 |
The present invention provides, in part, compounds of Formula I and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salt...
|
|
WO/2017/001655A1 |
Inhibitors of HBV replication of Formula (I-A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to pr...
|
|
WO/2016/130818A1 |
The present invention relates to compounds according to Formula (I-l) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
|
|
WO/2016/071499A1 |
The present invention relates to the use of substituted 3-pyridyl heterobicyclic compounds of formula I as agrochemical pesticides. Furthermore, the present invention relates to novel substituted 3-pyridylheterobicyclic compounds of form...
|
|
WO/2016/067009A1 |
This invention relates toantibacterial drug compounds containing a tricyclic ring system and pharmaceutical formulations thereof. The compounds are useful in the treatment of bacterial and mycobacterial infections, and particularly tuber...
|
|
WO/2015/123230A1 |
The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions cont...
|
|
WO/2015/061426A1 |
Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N 6 -[(3-halothien-2-yl)methyl]adenosine, N 6 -[...
|
|
WO/2015/038661A1 |
Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositi...
|
|
WO/2015/027214A1 |
In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6- carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine rec...
|
|
WO/2015/027204A1 |
In one aspect, the invention relates to substituted thieno[2,3-b]pyridine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (...
|
|
WO/2014/164428A1 |
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions contai...
|
|
WO/2014/152275A1 |
This invention relates to novel NS5B polymerase inhibitors and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of tr...
|
|
WO/2014/140299A1 |
The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatm...
|
|
WO/2014/140313A1 |
The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, f...
|
|
WO/2014/092100A1 |
The purpose of the invention is to provide a compound or salt thereof that is useful as an agent for the prevention or treatment of epilepsy, neurodegenerative disease, and the like. The invention pertains to compounds represented by for...
|
|
WO/2014/043272A1 |
Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricycli...
|
|
WO/2012/158933A9 |
The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.
|
|
WO/2013/148537A1 |
The present invention provides spirobicyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, diff...
|
|
WO/2013/139697A1 |
The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I ar...
|
|
WO/2013/104613A1 |
The invention relates to a compound of formula (I) wherein A, B, D and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2013/046029A1 |
The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention prov...
|
|
WO/2013/033245A1 |
The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds...
|
|
WO/2013/016441A1 |
Novel oxoisoindoline sulfonamide integrase inhibitors are useful to inhibit HIV activity, and are therefore suitable for treatment or prophylaxis of HIV infection, for example in the treatment or prevention of AIDS. In particular embodim...
|
|
WO/2012/120056A1 |
The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
|
|
WO/2012/120052A1 |
The invention relates to the compounds of formula (I) and physiologically acceptable salts thereof. The compounds are suitable, e.g., for treating hyperglycemia.
|
|
WO/2012/112345A1 |
This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection o...
|
|
WO/2012/075048A2 |
Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially sp...
|
|
WO/2012/006760A1 |
The present invention describes and claims compounds of the Structural Formula (I), Structural Formula (II), or Structural Formula (III). In Formula (I), R1, R2, R3 and R3' are -H or methyl, or R3 and R3' taken together form a double bon...
|
|
WO/2011/151348A1 |
This invention relates to heterocyclic amino acid derivatives suitable for labeling or already labeled with 18F or 19F, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compos...
|
|
WO/2011/147828A1 |
This invention relates to compounds of formula II: wherein R1, R2, ProtSH, and ProtNH are as defined, to processes for the synthesis of ectainascidins of formula I from compounds of formula II, and to processes for the synthesis of compo...
|
|
WO/2011/121105A1 |
Compound having Formula (I) and pharmaceutically acceptable salts or solvates thereof, their pharmaceutical formulations and use as HIV inhibitors.
|
|
WO/2011/116336A1 |
Disclosed is a compound of the formula (I) or a pharmaceutically acceptable salt thereof:(I) in which R1, R2, R3, and R4 are defined herein and pharmaceutical compositions thereof. Further provided is a method of treating various disorde...
|
|
WO/2011/095057A1 |
Benzimidazole derivatives and pharmaceutical compositions and use thereof are disclosed. Benzimidazole derivatives represented by general formula (I) or their stereoisomers, pharmaceutically acceptable compositions and solvates thereof a...
|
|
WO/2011/045330A1 |
Compound having formula (I), wherein - W is NH-, -N(CH3)- or piperazine, - X is a bond, -C(=O)- or S(=O)2-, - Y is C3-7alkylene, and - Z is NH-C(=O)- or -O-, and pharmaceutically acceptable salts thereof, their pharmaceutical formulation...
|
|
WO/2011/019173A2 |
The present invention relates to a compound containing 5-membered heterocycles, to an organic light-emitting device using same, and to a terminal comprising the latter.
|
|
WO/2010/071213A1 |
Provided is a resin composition which contains polyester and has no odor caused by a free isocyanate compound. This resin composition contains a terminal-modified polyester (component A) and a compound (component B) which has one carbodi...
|
|
WO/2010/037069A2 |
The invention provides optical agents, including compositions, preparations and formulations, and methods of using and making optical agents. Optical agents of the present invention include dyes, and derivatives thereof, having a fused r...
|
|
WO/2010/031054A1 |
Compositions and methods for treating epilepsy and epileptic syndromes are described herein. The compositions and methods include therapeutically effective amounts of one or more dimebolins, or pharmaceutically acceptable salts thereof.
|
|
WO/2010/028116A1 |
Macrocyclic derivative compounds that inhibit protein kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of p...
|
|
WO/2010/027567A2 |
The present invention relates to novel Tricyclic Spirocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Spirocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced ai...
|
|
WO/2010/018233A1 |
Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Y, R1, R2, R4 and n have the meaning defined in the claims. The present invention also relates to proc...
|
|
WO/2010/017093A2 |
Trans-hexahydrobenzo[a]phenanthridines of the formula (I) wherein X, Y, R1, R2, R3, R4, R5, R6, and R7 are as defined herein, are disclosed. Pharmaceutical formulations including such compounds, and methods of using such compounds for tr...
|
|
WO/2010/003658A1 |
Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates t...
|
|
WO/2009/093009A1 |
A series of fused tricyclic thiophene derivatives, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in t...
|
|
WO/2009/069147A2 |
An improved process for preparation of triazol-benzodiazepine derivatives, such as alprazolam, triazolam, brotizolam and etizolam, is presented. The process comprises a cyclization reaction of compound Formula (B) in toluene with catalyt...
|
|
WO/2009/052288A1 |
The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable composit...
|
|
WO/2009/010785A1 |
A class of macrocyclic compounds of formula (I), wherein R7,A,Ar, B,D, F, M, Q1, Q2, W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided....
|
